Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Expected to Announce Quarterly Sales of $11.70 Million

Equities analysts expect Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) to post sales of $11.70 million for the current quarter, according to Zacks. Five analysts have issued estimates for Dicerna Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $10.00 million and the highest estimate coming in at $12.93 million. Dicerna Pharmaceuticals reported sales of $1.55 million during the same quarter last year, which indicates a positive year-over-year growth rate of 654.8%. The company is expected to issue its next quarterly earnings results on Monday, November 4th.

According to Zacks, analysts expect that Dicerna Pharmaceuticals will report full-year sales of $37.25 million for the current year, with estimates ranging from $28.80 million to $48.10 million. For the next fiscal year, analysts forecast that the firm will post sales of $59.50 million, with estimates ranging from $15.00 million to $100.50 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The company had revenue of $5.68 million for the quarter, compared to analyst estimates of $10.95 million. Dicerna Pharmaceuticals had a negative return on equity of 50.30% and a negative net margin of 737.93%.

Several analysts recently commented on the stock. Cowen restated a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, July 2nd. B. Riley set a $24.00 price target on shares of Dicerna Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, July 3rd. Chardan Capital restated a “buy” rating and set a $18.00 price target on shares of Dicerna Pharmaceuticals in a report on Tuesday, August 13th. BidaskClub upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 13th. Finally, HC Wainwright set a $22.00 price target on shares of Dicerna Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 26th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Dicerna Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $21.57.

In other Dicerna Pharmaceuticals news, insider James B. Weissman sold 14,680 shares of Dicerna Pharmaceuticals stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $13.07, for a total value of $191,867.60. Following the completion of the sale, the insider now directly owns 9,800 shares in the company, valued at $128,086. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 21.28% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quantamental Technologies LLC lifted its stake in Dicerna Pharmaceuticals by 94.4% in the second quarter. Quantamental Technologies LLC now owns 3,500 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,700 shares during the last quarter. Bank of Montreal Can acquired a new stake in Dicerna Pharmaceuticals in the second quarter valued at approximately $68,000. Athanor Capital LP acquired a new stake in Dicerna Pharmaceuticals in the second quarter valued at approximately $233,000. Marshall Wace North America L.P. lifted its stake in Dicerna Pharmaceuticals by 261.6% in the first quarter. Marshall Wace North America L.P. now owns 17,886 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 12,939 shares during the last quarter. Finally, Virtus ETF Advisers LLC bought a new position in shares of Dicerna Pharmaceuticals in the second quarter valued at approximately $285,000. Hedge funds and other institutional investors own 82.04% of the company’s stock.

Shares of DRNA stock traded up $0.70 during trading on Friday, hitting $14.88. 206,700 shares of the company were exchanged, compared to its average volume of 423,013. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.65 and a current ratio of 3.65. The firm has a market capitalization of $968.66 million, a price-to-earnings ratio of -12.40 and a beta of 2.21. The business’s 50-day simple moving average is $14.22 and its 200 day simple moving average is $13.97. Dicerna Pharmaceuticals has a twelve month low of $9.31 and a twelve month high of $16.95.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Featured Article: Investing strategies using the yield curve

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.